1.52Open1.52Pre Close0 Volume578 Open Interest210.00Strike Price0.00Turnover66.08%IV17.22%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry1.52Extrinsic Value100Contract SizeAmericanOptions Type-0.0868Delta0.0044Gamma165.68Leverage Ratio-0.1631Theta-0.0100Rho-14.38Eff Leverage0.0857Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet